지씨셀
Financials
Valuation Metrics
지씨셀's Market Cap is ₩1588B. At end of 2025 it was ₩3926B. Ranked #923 of 2,410 in KR market (top 38%), #437 of 1,631 on KOSDAQ (top 27%), #109 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 47%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 158.79B KRW | KR#923/2,410 Sec#109/231 |
| Revenue | 162.00B KRW | KR#1,135/2,410 Sec#68/231 |
| Net Income | -246.86B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 303.69B KRW | KR#1,029/2,410 Sec#69/231 |
| Net Assets | 190.38B KRW | KR#979/2,410 Sec#69/231 |
| Employees | 811 | KR#308/2,410 Sec#26/231 |
| Value | ||
| P/B | 0.83x | KR#1,382/2,410 Sec#85/231 |
| P/S | 0.98x | KR#1,441/2,410 Sec#82/231 |
| FCF Yield | 4.99% | KR#877/2,410 Sec#51/231 |
| Profitability | ||
| ROE | -129.67% | KR#2,356/2,410 Sec#222/231 |
| ROA | -81.29% | KR#2,379/2,410 Sec#224/231 |
| Op. Margin | -6.70% | KR#1,909/2,410 Sec#127/231 |
| Revenue Growth | -4.97% | KR#1,761/2,410 Sec#168/231 |
| Financial Health | ||
| Debt Ratio | 59.52% | KR#1,083/2,410 Sec#126/231 |
| Total Debt | 51.61B KRW | KR#995/2,410 Sec#68/231 |
| FCF | 7.92B KRW | KR#778/2,410 Sec#45/231 |
| Cash | 1.46B KRW | KR#2,290/2,410 Sec#218/231 |
| Current Ratio | 0.52x | KR#2,123/2,410 Sec#206/231 |
| Dividend | ||
| Div. Growth | -71.42% | KR—/2,410 Sec—/231 |
| Performance | ||
| 1Y Return | -56.21% | KR#2,028/2,410 Sec#181/231 |
| 1M Return | -31.07% | KR#2,213/2,410 Sec#218/231 |
| From 52W High | -64.67% | KR#1,846/2,410 Sec#154/231 |
| 1Y MDD | -64.55% | KR#1,690/2,410 Sec#142/231 |
| Trading | ||
| Volume | 50,011 shares | KR#929/2,410 Sec#95/231 |
| Trading Value | 498.2M KRW | KR#774/2,410 Sec#82/231 |
| Foreign Own. | 3.39% | KR#1,177/2,410 Sec#108/231 |
| Per Share | ||
| EPS | -15,624 KRW | KR—/2,410 Sec—/231 |
| BPS | 12,049 KRW | KR#854/2,410 Sec#60/231 |
Company Info
Established in 2011 through the acquisition of a cell therapy business, this company expanded its operations by merging with Green Cross Cell in 2021. It encompasses the entire process of research and development, manufacturing, commercialization, and distribution within the cell and gene therapy field, offering cell therapies, specimen testing services, and bio-logistics. The company focuses on developing next-generation cell therapies such as CAR-NK and CAR-T, and is expanding indications to autoimmune diseases in collaboration with US company Artiva.